Changing the gameplan for
cancer patients
ZTX® finds the most effective treatments for each cancer patient within 5 days.
Today 2 of 3 cancer patients are treated inneffectively
Every year, more than 20 million persons are diagnosed with cancer, resulting in over 10 million deaths.
BioReperia provides a new unique way of individualizing cancer treatment for all cancer patients through our platform ZTX®PREDICT. Our platform can determine in only 5 days which treatment is most effective for each cancer patient and provide answers as to whether the patient is at risk of developing metastases.
BioReperia is ready to revolutionize the basis for how we treat cancer patients, making precision oncology accessible worldwide.
One platform multiple purposes
BioReperia is a privately owned company that has commercialized technology developed at Linköping University in Sweden.
The proprietary, CE-certified Zebrafish Tumor Xenograft (ZTX®) platform is the first of its kind, functional biomarker platform that is sold as a service, providing clinical decision support and patient stratification for clinical trials.
Treatment outcome predictions using ZTX®PREDICT are more accurate and faster than other available methods and add information about metastasis risk. Today there are no other reliable methods available on the market for predicting progression to metastatic disease, making ZTX®PREDICT a pioneering advancement in personalized medicine.
Furthermore, BioReperia is also offering its product for drug discovery and clinical research, ZTX®ONCOLEADS. ZTX®ONCOLEADS facilitates rapid, cost-effective assessment of new cancer treatments, especially immunotherapies and targeted therapies.
A fast and growing business
Sales growth of 50-150% in previous years, with over 80% recurrent customers globally.
The graph shows turnover in EUR.